Wells Fargo
ARTV

Wells Fargo’s Artiva Biotherapeutics ARTV Stock Holding History

Wells Fargo’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.66K Hold
1,500
– – ﹤0.01% 5976
2025
Q4 		$6.43K Sell
1,500
-200
-12% -$755 ﹤0.01% 6039
2025
Q3 		$4.88K Sell
1,700
-364
-18% -$974 ﹤0.01% 6079
2025
Q2 		$3.12K Sell
2,064
-10,595
-84% -$22.3K ﹤0.01% 6151
2025
Q1 		$38K Buy
12,659
+4,043
+47% +$21.8K ﹤0.01% 5489
2024
Q4 		$86.8K Buy
8,616
+3,361
+64% +$40.4K ﹤0.01% 5274
2024
Q3 		$81.2K Buy
+5,255
New +$60.9K ﹤0.01% 5136

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Wells Fargo's ARTV Position: Q1 2026 in Review

Wells Fargo held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 1,500 shares worth $9.66K. The position accounts for ﹤0.01% of the portfolio, ranked #5976.

Wells Fargo first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $86.8K in Q4 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Wells Fargo held 1,500 shares of Artiva Biotherapeutics worth $9.66K as of Q1 2026.
  • Wells Fargo left its Artiva Biotherapeutics share count unchanged in Q1 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5976 holding.
  • Wells Fargo first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Wells Fargo's Artiva Biotherapeutics position peaked at $86.8K in Q4 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.